1291 related articles for article (PubMed ID: 26011542)
1. 53BP1 suppresses epithelial-mesenchymal transition by downregulating ZEB1 through microRNA-200b/429 in breast cancer.
Kong X; Ding X; Li X; Gao S; Yang Q
Cancer Sci; 2015 Aug; 106(8):982-9. PubMed ID: 26011542
[TBL] [Abstract][Full Text] [Related]
2. Loss of the polycomb protein Mel-18 enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer.
Lee JY; Park MK; Park JH; Lee HJ; Shin DH; Kang Y; Lee CH; Kong G
Oncogene; 2014 Mar; 33(10):1325-35. PubMed ID: 23474752
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-200b regulates cell proliferation, invasion, and migration by directly targeting ZEB2 in gastric carcinoma.
Kurashige J; Kamohara H; Watanabe M; Hiyoshi Y; Iwatsuki M; Tanaka Y; Kinoshita K; Saito S; Baba Y; Baba H
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S656-64. PubMed ID: 22311119
[TBL] [Abstract][Full Text] [Related]
4. Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer.
Rhodes LV; Martin EC; Segar HC; Miller DF; Buechlein A; Rusch DB; Nephew KP; Burow ME; Collins-Burow BM
Oncotarget; 2015 Jun; 6(18):16638-52. PubMed ID: 26062653
[TBL] [Abstract][Full Text] [Related]
5. Downregulated microRNA-200a promotes EMT and tumor growth through the wnt/β-catenin pathway by targeting the E-cadherin repressors ZEB1/ZEB2 in gastric adenocarcinoma.
Cong N; Du P; Zhang A; Shen F; Su J; Pu P; Wang T; Zjang J; Kang C; Zhang Q
Oncol Rep; 2013 Apr; 29(4):1579-87. PubMed ID: 23381389
[TBL] [Abstract][Full Text] [Related]
6. MiR-652 inhibits acidic microenvironment-induced epithelial-mesenchymal transition of pancreatic cancer cells by targeting ZEB1.
Deng S; Li X; Niu Y; Zhu S; Jin Y; Deng S; Chen J; Liu Y; He C; Yin T; Yang Z; Tao J; Xiong J; Wu H; Wang C; Zhao G
Oncotarget; 2015 Nov; 6(37):39661-75. PubMed ID: 26498682
[TBL] [Abstract][Full Text] [Related]
7. E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells.
Tryndyak VP; Beland FA; Pogribny IP
Int J Cancer; 2010 Jun; 126(11):2575-83. PubMed ID: 19839049
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibitor-resistant cells cause EMT-induction via suppression of E-cadherin by miR-200 and ZEB1.
Asakura T; Yamaguchi N; Ohkawa K; Yoshida K
Int J Oncol; 2015 May; 46(5):2251-60. PubMed ID: 25738863
[TBL] [Abstract][Full Text] [Related]
9. Loss of MicroRNA-101 Promotes Epithelial to Mesenchymal Transition in Hepatocytes.
Zhao S; Zhang Y; Zheng X; Tu X; Li H; Chen J; Zang Y; Zhang J
J Cell Physiol; 2015 Nov; 230(11):2706-17. PubMed ID: 25808945
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-34a targets epithelial to mesenchymal transition-inducing transcription factors (EMT-TFs) and inhibits breast cancer cell migration and invasion.
Imani S; Wei C; Cheng J; Khan MA; Fu S; Yang L; Tania M; Zhang X; Xiao X; Zhang X; Fu J
Oncotarget; 2017 Mar; 8(13):21362-21379. PubMed ID: 28423483
[TBL] [Abstract][Full Text] [Related]
11. miR-448 inhibits the epithelial-mesenchymal transition in breast cancer cells by directly targeting the E-cadherin repressor ZEB1/2.
Ma P; Ni K; Ke J; Zhang W; Feng Y; Mao Q
Exp Biol Med (Maywood); 2018 Mar; 243(5):473-480. PubMed ID: 29368542
[TBL] [Abstract][Full Text] [Related]
12. Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells.
Ahmad A; Aboukameel A; Kong D; Wang Z; Sethi S; Chen W; Sarkar FH; Raz A
Cancer Res; 2011 May; 71(9):3400-9. PubMed ID: 21389093
[TBL] [Abstract][Full Text] [Related]
13. Restin suppressed epithelial-mesenchymal transition and tumor metastasis in breast cancer cells through upregulating mir-200a/b expression via association with p73.
Lu Z; Jiao D; Qiao J; Yang S; Yan M; Cui S; Liu Z
Mol Cancer; 2015 May; 14():102. PubMed ID: 25972084
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-33b inhibits lung adenocarcinoma cell growth, invasion, and epithelial-mesenchymal transition by suppressing Wnt/β-catenin/ZEB1 signaling.
Qu J; Li M; An J; Zhao B; Zhong W; Gu Q; Cao L; Yang H; Hu C
Int J Oncol; 2015 Dec; 47(6):2141-52. PubMed ID: 26459797
[TBL] [Abstract][Full Text] [Related]
15. Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells.
Manavalan TT; Teng Y; Litchfield LM; Muluhngwi P; Al-Rayyan N; Klinge CM
PLoS One; 2013; 8(4):e62334. PubMed ID: 23626803
[TBL] [Abstract][Full Text] [Related]
16. UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC.
Jin D; Guo J; Wu Y; Du J; Wang X; An J; Hu B; Kong L; Di W; Wang W
Theranostics; 2019; 9(7):2036-2055. PubMed ID: 31037155
[No Abstract] [Full Text] [Related]
17. MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways.
Li X; Roslan S; Johnstone CN; Wright JA; Bracken CP; Anderson M; Bert AG; Selth LA; Anderson RL; Goodall GJ; Gregory PA; Khew-Goodall Y
Oncogene; 2014 Jul; 33(31):4077-88. PubMed ID: 24037528
[TBL] [Abstract][Full Text] [Related]
18. An hTERT/ZEB1 complex directly regulates E-cadherin to promote epithelial-to-mesenchymal transition (EMT) in colorectal cancer.
Qin Y; Tang B; Hu CJ; Xiao YF; Xie R; Yong X; Wu YY; Dong H; Yang SM
Oncotarget; 2016 Jan; 7(1):351-61. PubMed ID: 26540342
[TBL] [Abstract][Full Text] [Related]
19. Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition.
Su CM; Lee WH; Wu AT; Lin YK; Wang LS; Wu CH; Yeh CT
J Nutr Biochem; 2015 Jun; 26(6):675-85. PubMed ID: 25792283
[TBL] [Abstract][Full Text] [Related]
20. microRNA-200c modulates the epithelial-to-mesenchymal transition in human renal cell carcinoma metastasis.
Wang X; Chen X; Wang R; Xiao P; Xu Z; Chen L; Hang W; Ruan A; Yang H; Zhang X
Oncol Rep; 2013 Aug; 30(2):643-50. PubMed ID: 23754305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]